TrialClinical cancer research : an official journal of the American Association for Cancer Research2025

FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

William F Maguire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.